Manage transplant patients with confidence
The Hologic Transplant portfolio continues the promise of innovation through life-changing viral testing, now expanded to include critical testing of post-transplant infection monitoring. The Aptima® CMV Quant assay* will be the first in a series of quantitative assays to support immunocompromised patient management following transplant surgery. Assays to also quantitate EBV and BKV are currently in development as part of the transplant portfolio, which runs on the Panther® and Panther Fusion® systems. These assays can be run in conjunction with other Aptima® and Panther Fusion® assays on the same platform. This consolidated menu streamlines workflow, providing a solution to the challenges faced by today's molecular lab.
Applied innovation in virology testing
Hologic’s viral load portfolio has a legacy of innovation and leadership in the United States. This legacy began with the FDA approval of qualitative NAATs for HIV-1 and HCV in the early 2000s. The Panther system menu now includes diagnosis and viral load testing for HIV-1 and Hepatitis C, viral load testing for Hepatitis B, and expands to viral load testing for transplant infections, starting with CMV.
Aptima® CMV Quant assay*: Accurate results for successful monitoring and treatment strategy
Cytomegalovirus (CMV) is member of Herpesviridae Family and is an enveloped, double-stranded DNA virus. Globally, 40-60% of the adult population have had prior CMV infection and could exceed 90% in some patient populations.1 CMV is usually asymptomatic in healthy individuals but remains in the body in a latent state. For patients undergoing solid organ or hematopoietic stem cell transplant, CMV infection and reactivation can lead to serious complications. If left untreated, CMV infection can lead to severe disease, transplant rejection, and death.
The Third International Consensus Guidelines on the Management of Cytomegalovirus recommends quantitative nucleic acid amplification testing (QNAT) as the preferred method of monitoring CMV infection in patients post transplantation.2 This use of QNAT assays calibrated to the World Health Organization (WHO) International Standard, like the Aptima CMV Quant assay,* decreases variability in results resulting in more standardized care.
Proven assay performance joins Panther system automation
The Aptima CMV Quant assay* provides accurate, highly reproducible viral quantitation that provides confidence in ensuring excellence in the clinical management of patients. This proven performance, combined with the benefits of Panther system automation, promotes flexibility and operational efficiency for viral load testing success in molecular labs across the world.